Molecules evolved
in nature

ATYR1940 HEALTHY SUBJECTS (001) TRIAL: PHASE 1

In the first quarter of 2014, we completed a double-blind, placebo-controlled Phase 1 clinical trial of ATYR1940, in which we assessed its safety and tolerability in 32 healthy subjects. ATYR1940 was shown to be well tolerated at all doses tested, and no serious adverse events were reported. Based on the favorable clinical safety, pharmacokinetic and immunogenicity profile of ATYR1940 in this trial, we decided to advance ATYR1940 into clinical trials of RMIC patients.

© 2007 - 2018   aTyr Pharma.   Legal   Privacy Policy